Table 1 Cancer group characteristics (n = 84)
From: Impact of cancer occurrence on health-related quality of life: A longitudinal pre-post assessment
| Â | n | proportion | mean | sd a |
|---|---|---|---|---|
Site | Â | Â | Â | Â |
   Breast | 18 | 21.4 |  |  |
   Cutaneous | 26 | 30.9 |  |  |
   Colo-rectal | 11 | 13.1 |  |  |
   Gynaecological | 2 | 2.4 |  |  |
   Hematologic | 3 | 3.6 |  |  |
   Prostate | 12 | 14.3 |  |  |
   Lung | 1 | 1.2 |  |  |
   Thyroid | 8 | 9.5 |  |  |
   Bladder | 2 | 2.4 |  |  |
   Other | 1 | 1.2 |  |  |
Stage at diagnosis of solid cancer | Â | Â | Â | Â |
   0 (in situ) | 6 | 7.4 |  |  |
   I | 43 | 55.6 |  |  |
   II | 28 | 32.1 |  |  |
   III | 3 | 3.7 |  |  |
   Unknown | 1 | 1.2 |  |  |
Time between diagnosis and T2 QoL assessment (months) | Â | Â | 15.2 | 7.9 |
Treatment before T2 QoL assessment | Â | Â | Â | Â |
   Surgery | 74 | 88.1 |  |  |
   Time between treatment and T2 (months) |  |  | 15.6 | 7.7 |
   Radiotherapy | 18 | 21.4 |  |  |
   Time between treatment and T2 (months) |  |  | 13.9 | 8.4 |
   Chemotherapy | 9 | 10.7 |  |  |
   Time between treatment and T2 (months) |  |  | 10.6 | 6.6 |
   No treatment | 7 | 8.3 |  |  |